Dhanireddy Kiran K, Xu He, Mannon Roslyn B, Hale Douglas A, Kirk Allan D
Transplantation Branch, National Institute of Diabets, Digestives and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Expert Opin Emerg Drugs. 2004 May;9(1):23-37. doi: 10.1517/eoed.9.1.23.32957.
Monoclonal antibodies have become valuable tools for the precise clinical manipulation of the immune system. These highly specific proteins have proven their usefulness in both the treatment and prevention of organ transplant rejection. Indeed, they are the centrepieces of many evolving regimens designed to reduce or eliminate the need for chronic immunosuppression. This manuscript will review the monoclonal antibodies that have made their way into the clinic either as experimental therapies or approved drugs. It will provide a general overview of this class of agents and their mechanisms of action. Standard therapies and potential new applications will be described.
单克隆抗体已成为精确临床操控免疫系统的宝贵工具。这些高度特异性的蛋白质在器官移植排斥反应的治疗和预防中均已证明其效用。事实上,它们是许多不断发展的治疗方案的核心,这些方案旨在减少或消除对慢性免疫抑制的需求。本手稿将回顾已进入临床的单克隆抗体,这些抗体或是作为实验性疗法,或是作为已获批药物。它将对这类药物及其作用机制进行总体概述。还将描述标准疗法和潜在的新应用。